SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001415889-13-002318
Filing Date
2013-11-14
Accepted
2013-11-14 16:14:25
Documents
10
Period of Report
2013-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q vsta10qsep302013.htm 10-Q 1225047
2 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER REQUIRED BY RULE 13A-14(A) UNDE ex31-1.htm EX-31.1 10942
3 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER REQUIRED BY RULE 13A-14(A) UNDE ex31-2.htm EX-31.2 11206
4 CERTIFICATION OF THE PRINCIPAL EXECUTIVE AND FINANCIAL OFFICERS REQUIRED BY RULE ex32.htm EX-32 6169
  Complete submission text file 0001415889-13-002318.txt   6290848

Data Files

Seq Description Document Type Size
5 vsta-20130930.xml EX-101.INS 929240
6 vsta-20130930.xsd EX-101.SCH 64598
7 vsta-20130930_cal.xml EX-101.CAL 52093
8 vsta-20130930_def.xml EX-101.DEF 141025
9 vsta-20130930_lab.xml EX-101.LAB 323330
10 vsta-20130930_pre.xml EX-101.PRE 235321
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-244-9990
VistaGen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 000-54014 | Film No.: 131220128
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences